Cite
Herring W, Pearson I, Purser M, et al. Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value Health. 2014;17(7):A633doi: 10.1016/j.jval.2014.08.2267.
Herring, W., Pearson, I., Purser, M., Nakhaipour, H. R., Haiderali, A., Wolowacz, S., & Jayasundara, K. (2014). Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A633. https://doi.org/10.1016/j.jval.2014.08.2267
Herring, W, et al. "Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A633. doi: https://doi.org/10.1016/j.jval.2014.08.2267
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost-Effectiveness of Ofatumumab Plus Chlorambucil in First Line Chronic Lymphocytic Leukemia in Canada. Value Health. 2014 Nov;17(7):A633. doi: 10.1016/j.jval.2014.08.2267. Epub 2014 Oct 26. PMID: 27202251.
Copy
Download .nbib